“We test ER expression in a metastatic biopsy once at the beginning of the patient’s journey,” explained Linden, “and we make decisions all along—when to give chemotherapy, when to use endocrine therapy, whether or not to use targeted agents—based on that one measurement. Since we know that ER expression can fluctuate, imaging with 18F-fluoroestradiol at various time points could help clinicians predict response to endocrine therapy and select optimal treatment in the future.”
18F-fluoroestradiol was approved by the U.S. Food and Drug Administration in May 2020.
Ad Statistics
Times Displayed: 365769
Times Visited: 7086 Quality remanufactured Certified Centrifuges at Great prices! Fully warranted and backed by a company you can trust! Call or click for a free quote today! www.Centrifugestore.com 800-457-7576
The authors of “18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2− Metastatic Breast Cancer” include Lanell M. Peterson, Fengting Yan, Jennifer M. Specht, Julie R. Gralow and Hannah M. Linden, Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington; Brenda F. Kurland, Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania; Alena Novakova-Jiresova, Department of Oncology, First Faculty of Medicine, Charles University and Thomayer Hospital, Prague, Czech Republic; Vijayakrishna K. Gadi, Division of Medical Oncology, University of Washington/Seattle Cancer Care Alliance, Seattle, Washington, and Clinical Research and Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington; Erin K. Schubert and David A. Mankoff, Department of Radiology, University of Pennsylvania, Philadelphia, Pennsylvania; Jeanne M. Link and Kenneth A. Krohn, Department of Diagnostic Radiology, Oregon Health and Science University, Portland, Oregon; and Janet F. Eary, Cancer Imaging Program, National Cancer Institute, Bethesda, Maryland.
About the Society of Nuclear Medicine and Molecular Imaging
The Journal of Nuclear Medicine (JNM) is the world’s leading nuclear medicine, molecular imaging and theranostics journal, accessed close to 10 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging—precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes.
Back to HCB News
